QUOTE AND NEWS
newratings.com  5 hrs ago  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and French drug maker Sanofi (SNYNF, SNY) announced Thursday positive topline results from phase 3 studies with Sarilumab in patients with rheumatoid arthritis. The companies noted that a...
newratings.com  May 20  Comment 
CANCOM SE: CANCOM SE divests group-subsidiary Imperia AG DGAP-News: CANCOM SE / Key word(s): Agreement CANCOM SE: CANCOM SE divests group-subsidiary Imperia AG 20.05.2015 /...
Market Intelligence Center  May 18  Comment 
After closing Friday at $50.52, Sanofi-Aventis (SNY) presents an attractive opportunity to get a 4.23% return in just 123 days, which is an annualized return of 12.56% (for comparison purposes only). To enter this trade, sell one Sep. '15 $50.00...
MedPage Today  May 14  Comment 
(MedPage Today) -- Yet another report of survival improvement with upfront docetaxel plus hormonal therapy.
GenEng News  May 13  Comment 
Selecta Biosciences today said it was expanding its three-year-old alliance with Sanofi focused on developing antigen-specific immunotherapies—with the potential to receive up to $300 million—and launching a separate ongoing research...
FiercePharma  May 12  Comment 
Afrezza wasn't expected to be the spinach that would give Sanofi's diabetes business instant, superhuman strength. But the inhaled insulin, launched in February under a marketing deal with MannKind, was supposed to help fuel sales growth.
TheStreet.com  May 8  Comment 
VALENCIA, Calif. (TheStreet) -- MannKind's first-quarter conference call on Friday morning didn't go well. Management admitted the Afrezza commercial launch is slower than expected. Cash burn and debt remains problems which need to be addressed...
FiercePharma  May 5  Comment 
Sanofi CEOs past and present are in line for big payouts after yesterday's annual meeting, as resolutions passed to line the pockets of ousted skipper Chris Viehbacher and new replacement Olivier Brandicourt. But shareholders aren't necessarily...
Forbes  May 1  Comment 
French drugmaker Sanofi continues to invest in vaccine development, but maintaining sales growth presents challenges.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki